Patients & ProvidersHow SelfWrap WorksCompanyNewsClinical Trial
All News

VenoStent Accepted into Y Combinator and Closes Oversubscribed SAFE Round

Jun 24, 2020

We are honored and pleased to announce our acceptance into Y Combinator and the closing of a $535,000 oversubscribed SAFE round.

Y Combinator

YC is a startup fund and program. Since 2005, YC has invested in over 2,000 companies, and the combined valuation of YC companies is over $155B. YC has programs and resources that support founders throughout the life of their company. The YC batch program helps founders as they build their product, talk to their customers, and raise funding. YC has the strongest founder network in the world, with built-in customers for their products and services. For the 4,000+ YC alumni, there’s always someone two steps behind and two steps in front to help guide you through every stage — regardless of industry.

The VenoStent team will be working directly with YC Partners Jared Friedman, Uri Lopatin, Michael Seibel, and Harj Taggar. YC will help VenoStent establish more strategic partnerships, aid fundraising and business development efforts, and expand the platform potential of its materials.

SAFE Round

VenoStent closed a $535,000 SAFE Round, which was $100K oversubscribed. This funding will allow VenoStent to conduct its first-in-human clinical trial, complete FDA-compliant good laboratory practices (GLP) large animal testing, enhance manufacturing capabilities, and further build out its team.

Led by Texas HALO Fund (THF), VenoStent was able to close and oversubscribe the round in less than three weeks when combining THF’s investment with those from Cowtown Angels and Activated Capital. THF, out of Houston, and Cowtown Angels, out of Fort Worth, also participated in VenoStent’s first two rounds of funding in 2018 and 2019, while Activated Capital is a new participant. Activated Capital is an opportunity zone fund that aims to provide greater financial and social returns by aligning within the communities in which they serve, rather than the traditional top-down investment approach.

SelfWrap is currently in the research and development phase and is not available for sale in any country. Investigational Device. Limited by Federal Law to Investigational Use.

COI Policy© 2024 VenoStent, Inc. All rights reserved.
2450 Holcombe Blvd, Suite J Houston, TX 77021
Follow Us